Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Dravet syndrome
Dravet syndrome
Stoke's Dravet syndrome med released from partial clinical hold as company eyes phase 3 plans
Fierce Biotech
Wed, 08/7/24 - 11:31 am
Stoke Therapeutics
Dravet syndrome
STK-001
clinical trials
Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect
Fierce Biotech
Mon, 06/17/24 - 11:29 am
Takeda
clinical trials
Ovid Therapeutics
Dravet syndrome
epilepsy
soticlestat
Stoke’s shares shoot up 90% as epilepsy drug slashes convulsive seizures
Fierce Biotech
Tue, 03/26/24 - 11:13 am
Stoke Therapeutics
antisense
seizures
Dravet syndrome
STK-001
Stoke faces new doubts in search for ‘Spinraza for epilepsy’
BioPharma Dive
Tue, 07/25/23 - 08:47 pm
Stoke Therapeutics
Dravet syndrome
epilepsy
STK-001
Stoke Looks to Pivotal Trial for Dravet Candidate
BioSpace
Mon, 11/14/22 - 07:01 pm
Stoke Therapeutics
Dravet syndrome
STK-001
clinical trials
CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
Businesswire
Wed, 07/20/22 - 09:36 am
CAMP4
funding
CNS
Dravet syndrome
UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022
BioPharma Dive
Wed, 01/19/22 - 11:12 am
UCB Pharma
Zogenix
Fintepla
Dravet syndrome
Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Endpoints
Tue, 08/25/20 - 09:57 pm
Ovid Therapeutics
clinical trials
Takeda
Dravet syndrome
Lennox-Gastaut Syndrome
GW Pharma
FDA Approves Zogenix's Drug for Rare Childhood Epilepsy
NY Times, NY
Fri, 06/26/20 - 09:46 am
FDA
Zogenix
epilepsy
Dravet syndrome
FDA pushes back decision on Zogenix epilepsy drug
BioPharma Dive
Thu, 02/27/20 - 11:41 pm
Zogenix
epilepsy
Fintepla
FDA
Dravet syndrome
New Data Could Boost Potential Approval of Zogenix's Epilepsy Drug
BioSpace
Fri, 10/25/19 - 10:42 pm
Zogenix
Fintepla
Dravet syndrome
epilepsy
Why Shares of Drugmaker Zogenix Dropped 11.4% in August
Motley Fool
Fri, 09/6/19 - 08:36 pm
Zogenix
Fintepla
Dravet syndrome
Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike
Endpoints
Thu, 06/27/19 - 11:42 am
Zogenix
FDA
Dravet syndrome
Fintepla
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D
Xconomy
Tue, 06/18/19 - 11:35 pm
Stoke Therapeutics
IPOs
Dravet syndrome
Stoke Therapeutics Files for $86 Million IPO
CP Wire
Fri, 05/24/19 - 10:33 am
Stoke Therapeutics
Dravet syndrome
IPOs
Stoke Therapeutics Files for $86 Million IPO
Fri, 05/24/19 - 09:39 am
Stoke Therapeutics
Dravet syndrome
FDA snubs Zogenix's anti-seizure drug, not happy with some sloppy, inadequate R&D work
Endpoints
Mon, 04/8/19 - 11:21 pm
Zogenix
Dravet syndrome
FDA
refuse to file letters
Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?
Motley Fool
Tue, 11/27/18 - 11:27 pm
GW Pharma
Epidiolex
Cannabidiol
clinical trials
Dravet syndrome
GW announces US launch of cannabinoid medicine for seizures
Pharmaceutical Business Review
Fri, 11/2/18 - 11:25 am
GW Pharma
Greenwich. Epidiolex
drug launches
Dravet syndrome
Lennox-Gastaut Syndrome
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
Xconomy
Thu, 07/12/18 - 09:59 am
Dravet syndrome
clinical trials
Zogenix
ZX008
FenPhen
GW Pharma
Epidiolex
Pages
1
2
next ›
last »